Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Seeman, P. Articles by Tallerico, T. Search for Related Content PubMed Citation Articles by Seeman, P. Articles by Tallerico, T. Neurotransmitters Other Neuroleptics

Rapid Release of Antipsychotic Drugs From Dopamine D₂ Receptors: An Explanation for Low Receptor Occupancy and Early Clinical Relapse Upon Withdrawal of Clozapine or Quetiapine

OBJECTIVE: In an attempt to understand the basis of early relapse after antipsychotic withdrawal, the objective of this study was to determine whether the low occupancy of dopamine D₂ receptors by clozapine and by quetiapine, as seen by brain imaging, could arise from a rapid release of some of the D₂-bound clozapine or quetiapine by the brain imaging compounds and by the action of a physiological concentration of dopamine. METHOD: Human cloned D₂ receptors were first pre-equilibrated with the [³H]antipsychotic drug, after which raclopride, iodobenzamide, or dopamine (at the physiological concentration in the synapse) was added, and the time course of release of the [³H]antipsychotic from the D₂ receptor was measured. RESULTS: Within 5 minutes, low concentrations of raclopride and iodobenzamide displaced appreciable amounts of [³H]clozapine and [³H]quetiapine from the D₂ receptors but, during the course of 1 hour, did not displace any of the other antipsychotic [^[3H]ligands. [³H]Clozapine and [³H]quetiapine, moreover, were displaced by dopamine (100 nM) at least 100 times faster than the other antipsychotic [³H]ligands. CONCLUSIONS: Clozapine and quetiapine are loosely bound to the D₂ receptor, and the injected radioactive ligand at its peak concentration may displace some of the D₂-bound antipsychotic drug, resulting in apparently low D₂ occupancies. Therefore, under clinical brain imaging conditions with [¹¹C]raclopride, D₂ occupancies by clozapine and by quetiapine may be higher than currently estimated. These considerations may result in high levels of the D₂ receptors being occupied by therapeutic doses of clozapine or quetiapine. The rapid release of clozapine and quetiapine from D₂ receptors by endogenous dopamine may contribute to low D₂ receptor occupancy and to early clinical relapse upon withdrawal of these medications.

This article has been cited by other articles:

				J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al. Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection Pharmacol. Rev., September 1, 2008; 60(3): 358 - 403. [Abstract] [Full Text] [PDF]

				S Potvin, T Pampoulova, A Mancini-Marie, O Lipp, R-H Bouchard, and E Stip Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 796 - 798. [Abstract] [Full Text] [PDF]

				P. SEEMAN An Update of Fast-Off Dopamine D2 Atypical Antipsychotics Am J Psychiatry, October 1, 2005; 162(10): 1984 - 1985. [Full Text] [PDF]

				G. REMINGTON Rational pharmacotherapy in early psychosis The British Journal of Psychiatry, August 1, 2005; 187(48): s77 - s84. [Abstract] [Full Text] [PDF]

				M. Harrow, L. S Grossman, T. H Jobe, and E. S Herbener Do Patients with Schizophrenia Ever Show Periods of Recovery? A 15-Year Multi-Follow-up Study Schizophr Bull, July 1, 2005; 31(3): 723 - 734. [Abstract] [Full Text] [PDF]

				G. P. Reynolds Receptor Mechanisms in the treatment of Schizophrenia J Psychopharmacol, September 1, 2004; 18(3): 340 - 345. [Abstract] [PDF]

				P. Seeman Atypical Antipsychotics: Mechanism of Action Focus, January 1, 2004; 2(1): 48 - 58. [Abstract] [Full Text] [PDF]

				Y. Chen, D. L. Levy, S. Sheremata, K. Nakayama, S. Matthysse, and P. S. Holzman Effects of Typical, Atypical, and No Antipsychotic Drugs on Visual Contrast Detection in Schizophrenia Am J Psychiatry, October 1, 2003; 160(10): 1795 - 1801. [Abstract] [Full Text] [PDF]

				C. Greenwood-Smith, D. I. Lubman, and D. J. Castle Serum Clozapine Levels: A Review of Their Clinical Utility J Psychopharmacol, June 1, 2003; 17(2): 234 - 238. [Abstract] [PDF]

				G. J. E. Schmitt, E. M. Meisenzahl, S. Dresel, K. Tatsch, B. Rossmuller, T. Frodl, U. W. Preuss, K. Hahn, and H.-j. Moller Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine J Psychopharmacol, May 1, 2002; 16(3): 200 - 206. [Abstract] [PDF]

				A E Hensiek and M R Trimble Relevance of new psychotropic drugs for the neurologist J. Neurol. Neurosurg. Psychiatry, March 1, 2002; 72(3): 281 - 285. [Full Text] [PDF]

				S. Kapur and P. Seeman Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis Am J Psychiatry, March 1, 2001; 158(3): 360 - 369. [Abstract] [Full Text]

				P. G. Strange Antipsychotic Drugs: Importance of Dopamine Receptors for Mechanisms of Therapeutic Actions and Side Effects Pharmacol. Rev., March 1, 2001; 53(1): 119 - 134. [Abstract] [Full Text] [PDF]

				M. J. Millan Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 853 - 861. [Abstract] [Full Text]

				D. Taylor Low dose typical antipsychotics - a brief evaluation Psychiatr. Bull., December 1, 2000; 24(12): 465 - 468. [Full Text]

				C. M. E. STEPHENSON, V. BIGLIANI, H. M. JONES, R. S. MULLIGAN, P. D. ACTON, D. VISVIKIS, P. J. ELL, R. W. KERWIN, and L. S. PILOWSKY Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo: [123I]-epidepride single photon emission tomography(SPET) study The British Journal of Psychiatry, November 1, 2000; 177(5): 408 - 415. [Abstract] [Full Text] [PDF]

				P. Seeman and S. Kapur Schizophrenia: More dopamine, more D2 receptors PNAS, July 5, 2000; 97(14): 7673 - 7675. [Full Text] [PDF]

				A. J. Goudie What is the clinical significance of the discontinuation syndrome seen with clozapine? J Psychopharmacol, March 1, 2000; 14(2): 188 - 190. [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us